Physician profile
Michael Fabrizio
NPI 1427036664
$1,541,793.67
in general payments reported to CMS, 2019-2025
56 companies · $131K in 2025
The $131K reported for 2025 was more than what 99% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $221K · 2020: $217K · 2021: $114K · 2022: $131K · 2023: $168K · 2024: $560K · 2025: $131K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $452K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $306K · Travel and Lodging: $77K · Honoraria: $13K · Food and Beverage: $12K · Education: $177 · Grant: $125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $451,610.75 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $306,010.66 |
| Travel and Lodging | $76,830.28 |
| Honoraria | $12,598.00 |
| Food and Beverage | $11,578.99 |
| Education | $177.02 |
| Grant | $125.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Global Services, LLC | $350,909.68 | 2020-2025 | |
| Astellas Pharma US INC | $311,282.00 | 2019-2025 | Xtandi |
| Bayer Healthcare Pharmaceuticals INC. | $151,469.18 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $100,131.16 | 2019-2023 | Keytruda, Lynparza |
| Janssen Biotech, INC. | $93,286.39 | 2019-2025 | Erleada, Carvykti, Rybrevant |
| Janssen Research & Development, LLC | $91,490.33 | 2024 | |
| Urogpo LLC | $87,551.25 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $71,997.56 | 2023-2025 | Orgovyx |
| Dendreon Pharmaceuticals LLC | $60,448.52 | 2019-2024 | Provenge |
| Sn Holdings, LLC | $52,641.18 | 2021-2023 | |
| Astrazeneca Pharmaceuticals Lp | $49,628.01 | 2020-2024 | Lynparza, Imfinzi |
| Pfizer INC. | $24,233.92 | 2019-2024 | |
| Johnson & Johnson Health Care Systems INC. | $14,103.58 | 2022-2023 | |
| Karl Storz Endoscopy-America | $10,853.94 | 2019-2020 | |
| Myovant Sciences INC. | $10,191.00 | 2021-2022 |
Show all 55 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5,023,383.82 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Fabrizio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.